Sylvia Rothenberger

Dr. Sylvia Rothenberger

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SRSylvia Rothenberger
Sylvia Rothenberger
DHDaniel L. Hurdiss
Daniel L. Hurdiss
MWMarcel Walser
Marcel Walser
FMFrancesca Malvezzi
Francesca Malvezzi
JMJennifer Mayor
Jennifer Mayor
JTJakob Trimpert
Jakob Trimpert
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19).

15 June 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
JMJennifer Mayor
Jennifer Mayor
OEOlivier Engler
Olivier Engler
SRSylvia Rothenberger
Sylvia Rothenberger
Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available.

1 February 2007 in Journal of Virology
Verified
Journal Article
Open access
PDF file
CBChristophe Butticaz
Christophe Butticaz
OMOlivier Michielin
Olivier Michielin
JWJosiane Wyniger
Josiane Wyniger
Amalio TelentiAmalio Telenti
Amalio Telenti
SRSylvia Rothenberger
Sylvia Rothenberger
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interacts with CD4 within the endoplasmic reticula of infected cells and targets CD4 for degradation through interaction with β-TrCP1. Mammals possess a homologue of β-TrCP1, HOS, which is also named β-TrCP2. We show by coimmunoprecipitation experiments that β-TrCP2 binds Vpu and is able to induce CD4 down-modulation as efficiently as β-TrCP1. In two different cell lines, HeLa CD4 + and Jurkat, Vpu-mediated CD4 down-modulation could not be reversed through the individual silencing of endogenous β-TrCP1 or β-TrCP2 but instead required the two genes to be silenced simultaneously.

1 May 2019 in Virology
Verified
Journal Article
Closed access
GTGiulia Torriani
Giulia Torriani
JMJennifer Mayor
Jennifer Mayor
GZGert Zimmer
Gert Zimmer
KSKunz Stefan
Kunz Stefan
SRSylvia Rothenberger
Sylvia Rothenberger
OEOlivier Engler
Olivier Engler

17 November 2023 in Viruses
Verified
Journal Article
Open access
PDF file
RZRoland Züst
Roland Züst
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
NLNicole Liechti
Nicole Liechti
DSDenise Siegrist
Denise Siegrist
SRSarah Ryter
Sarah Ryter
OEOlivier Engler
Olivier Engler
When infecting humans, Andes orthohantavirus (ANDV) may cause a severe disease called hantavirus cardiopulmonary syndrome (HCPS). Following non-specific symptoms, the infection may progress to a syndrome of hemorrhagic fever combined with hyper-acute cardiopulmonary failure. The case fatality rate ranges between 25–40%, depending on the outbreak. In this study, we present the follow-up of a male patient who recovered from HCPS six years ago. We demonstrate that the ANDV genome persists within the reproductive tract for at least 71 months. Genome sequence analysis early and late after infection reveals a low number of mutations (two single nucleotide variants and one deletion), suggesting limited replication activity. We can exclude the integration of the viral genome into the host genome, since the treatment of the specimen with RNAse led to a loss of signal. We demonstrate a long-lasting, strong neutralizing antibody response using pseudovirions expressing the ANDV glycoprotein. Taken together, our results show that ANDV has the potential for sexual transmission.

22 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EZEmilie Zuercher
Emilie Zuercher
CBChristophe Butticaz
Christophe Butticaz
JWJosiane Wyniger
Josiane Wyniger
RMRaquel Martinez
Raquel Martinez
MBManuel Battegay
Manuel Battegay
TSthe Swiss HIV cohort study
the Swiss HIV cohort study
Epstein-Barr virus (EBV) is associated with several types of cancers including Hodgkin's lymphoma (HL) and nasopharyngeal carcinoma (NPC). EBV-encoded latent membrane protein 1 (LMP1), a multifunctional oncoprotein, is a powerful activator of the transcription factor NF-κB, a property that is essential for EBV-transformed lymphoblastoid cell survival. Previous studies reported LMP1 sequence variations and induction of higher NF-κB activation levels compared to the prototype B95-8 LMP1 by some variants. Here we used biopsies of EBV-associated cancers and blood of individuals included in the Swiss HIV Cohort Study (SHCS) to analyze LMP1 genetic diversity and impact of sequence variations on LMP1-mediated NF-κB activation potential. We found that a number of variants mediate higher NF-κB activation levels when compared to B95-8 LMP1 and mapped three single polymorphisms responsible for this phenotype: F106Y, I124V and F144I. F106Y was present in all LMP1 isolated in this study and its effect was variant dependent, suggesting that it was modulated by other polymorphisms. The two polymorphisms I124V and F144I were present in distinct phylogenetic groups and were linked with other specific polymorphisms nearby, I152L and D150A/L151I, respectively. The two sets of polymorphisms, I124V/I152L and F144I/D150A/L151I, which were markers of increased NF-κB activation in vitro, were not associated with EBV-associated HL in the SHCS. Taken together these results highlighted the importance of single polymorphisms for the modulation of LMP1 signaling activity and demonstrated that several groups of LMP1 variants, through distinct mutational paths, mediated enhanced NF-κB activation levels compared to B95-8 LMP1.